
Dr Arbour on the Role of Zoldonrasib in KRAS G12D–Mutant NSCLC
“Zoldonrasib was well tolerated across all dose levels, including in the subset of patients who were treated at the candidate recommended phase 2 dose of 1200 mg once daily.” Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering …